Neuronetics, Inc.
STIM Healthcare Medical Devices
Neuronetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $149.2 million, up 99.2% from fiscal 2024. In the quarter to June 2026, revenue grew 9.08%, EPS grew 66.7%, free cash flow grew 62.1% and total debt rose 10.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow STIM
Neuronetics, Inc. (STIM) P/E ratio
Neuronetics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 32 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| APYX Apyx Medical Corporation compare | n/m |
| LUCD Lucid Diagnostics Inc. compare | n/m |
| MXCT MaxCyte, Inc. compare | n/m |
| OWLT Owlet, Inc. compare | n/m |
| RXST RxSight, Inc. compare | n/m |
| INGN Inogen, Inc compare | n/m |
| STIM Neuronetics, Inc. | n/m |
| QTRX Quanterix Corporation compare | n/m |
| PROF Profound Medical compare | n/m |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)